DDInter770 DDInter1376
Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Fluvoxamine {u} (Compound) resembles {v} (Compound) Ridogrel
Fluvoxamine {u} (Compound) binds {v} (Gene) CYP3A4
Fluvoxamine {u} (Compound) upregulates {v} (Gene) CCNA1
Fluvoxamine {u} (Compound) palliates {v} (Disease) endogenous depression
Fluvoxamine {u} (Compound) downregulates {v} (Gene) HERPUD1
Fluvoxamine {u} (Compound) causes {v} (Side Effect) Accommodation disorder
Fluvoxamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Fluvoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Fluvoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tenecteplase
Fluvoxamine {u} may lead to a major life threatening interaction when taken with {v} Phenylpropanolamine
Fluvoxamine (Compound) resembles Ridogrel (Compound)
Fluvoxamine (Compound) binds CYP3A4 (Gene)
Fluvoxamine (Compound) upregulates CCNA1 (Gene)
Fluvoxamine (Compound) palliates endogenous depression (Disease)
Fluvoxamine (Compound) downregulates HERPUD1 (Gene)
Fluvoxamine (Compound) causes Accommodation disorder (Side Effect)
Fluvoxamine may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase
Fluvoxamine may lead to a major life threatening interaction when taken with Phenylpropanolamine